The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $318,488 Project Grant (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) to Dolor Therapeutics, LLC for the project "Optimizing Dual Therapy for Chronic Prostatitis/Chronic Pelvic Pain Syndrome." The goal is to develop an optimized oral formulation that combines a mast cell stabilizer and histamine receptor antagonist to treat chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS), a prevalent urological condition in men. The funding will support feasibility studies in dogs and mice to select the most suitable formulation with optimal absorption and exposure characteristics, laying the groundwork for a future Phase II STTR focused on optimization, stability, and manufacturing of the lead formulation.
Generated 3/18/25, 4:16 AM